Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $21.75.
Several brokerages recently issued reports on VNDA. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a report on Friday, May 26th. They issued a “buy” rating and a $18.00 price objective on the stock. CIBC restated an “outperform” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. Jefferies Group LLC restated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. Finally, TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th.
A number of hedge funds have recently modified their holdings of VNDA. Point72 Asset Management L.P. raised its stake in shares of Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares during the period. FMR LLC raised its stake in shares of Vanda Pharmaceuticals by 928.0% in the fourth quarter. FMR LLC now owns 996,271 shares of the biopharmaceutical company’s stock worth $15,891,000 after buying an additional 899,358 shares during the period. Vanguard Group Inc. raised its stake in shares of Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares during the period. Nexthera Capital LP acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth about $7,171,000. Finally, State Street Corp raised its stake in shares of Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock worth $27,935,000 after buying an additional 374,095 shares during the period. Institutional investors own 91.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Vanda Pharmaceuticals Inc. (VNDA) Target Price at $21.75” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/07/31/vanda-pharmaceuticals-inc-vnda-given-average-rating-of-buy-by-analysts-updated.html.
Vanda Pharmaceuticals (NASDAQ VNDA) traded down 1.111% on Friday, reaching $15.575. 137,242 shares of the company traded hands. The stock has a 50 day moving average of $15.78 and a 200-day moving average of $14.58. The stock’s market capitalization is $693.90 million. Vanda Pharmaceuticals has a 1-year low of $11.32 and a 1-year high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. The company had revenue of $37.42 million during the quarter, compared to analysts’ expectations of $38.35 million. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. On average, equities analysts anticipate that Vanda Pharmaceuticals will post ($0.70) EPS for the current year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
